More anesthesia machines added to correction for potential ventilation failure
The U.S. Food and Drug Administration (FDA) has designated a recent expansion of Draeger, Inc.’s Atlan anesthesia workstation correction as a Class I recall, the agency’s most serious recall classification.
What makes this action particularly noteworthy is that it expands a correction originally announced in October 2024, raising questions about the scope and duration of the underlying manufacturing issue.
The correction affects certain Draeger Atlan A350 and Atlan A350 XL anesthesia workstations used to deliver inhaled anesthesia and mechanical ventilation during surgical and diagnostic procedures involving adults, children, and neonates.
According to Draeger, a manufacturing defect involving the ventilator motor assembly may cause the piston ventilator to fail either before use or during active patient ventilation. If the failure occurs before a procedure, mechanical ventilation cannot be initiated. If it occurs during a procedure, the workstation displays a “Ventilator error!!!” alarm and automatic ventilation ceases.
Manual ventilation remains available and monitoring functions continue to operate.
Why This Matters
Mechanical ventilation is a critical life-support function during anesthesia. According to FDA, failure of the ventilation system could potentially result in hypoxia (oxygen deprivation), loss of lung recruitment, Bradycardia, cardiac arrest, or death.
Although no injuries or deaths have been reported, FDA classified both the original correction and the recent expansion as Class I actions because of the severity of potential patient harm.
What’s New?
The May 2026 action expands Draeger’s October 2024 correction to include additional Atlan A350 and A350 XL workstations. The company states that additional devices require replacement of the ventilator motor assembly due to the same manufacturing-related issue identified during the original correction.
Affected facilities may continue using the devices under constant supervision until Draeger completes replacement of the ventilator motor assembly. If ventilation failure occurs, clinicians are instructed to immediately switch to Manual/Spontaneous ventilation mode and manually ventilate the patient.
Regulatory Perspective
The expansion of a Class I field correction nearly two years after the original action is unusual and raises several important quality-system questions.
Was the affected population initially underestimated?
Were additional devices identified through complaint trending or service records?
Did subsequent investigations uncover a broader manufacturing impact?
How effective was the original correction strategy in identifying all affected units?
At present, neither FDA nor Draeger has reported injuries, deaths, or patient harm associated with the issue. That is significant.
In many Class I recalls involving life-support equipment, patient harm is often what drives regulatory escalation. In this case, the combination of alarm functionality, continued monitoring capability, and the availability of manual ventilation appears to have provided effective risk controls while corrective actions are implemented.
What Healthcare Facilities Should Do
Facilities using affected Atlan A350 and Atlan A350 XL anesthesia workstations should coordinate with Draeger representatives to schedule replacement of affected ventilator motor assemblies.
In addition, facilities can continue operating devices under close supervision, ensure clinical staff are aware of the correction, and be prepared to transition immediately to Manual/Spontaneous ventilation mode if a ventilator error occurs.
MDP Regulatory Perspective
This recall serves as a reminder that postmarket corrective actions do not always end with the initial field notification. Even well-executed investigations may continue to evolve as manufacturers analyze service records, complaint data, production history, and field performance trends.
For regulatory and quality professionals, one of the most important questions is not simply why the correction was expanded, but how the manufacturer identified the need for expansion and whether the processes used to identify affected devices were sufficiently robust during the original 2024 action.
As FDA and manufacturers continue to emphasize risk-based postmarket surveillance, this case demonstrates how corrective actions can remain active and evolve years after the initial field action is launched.
Links
Read the FDA’s announcement here.
Regulatory Snapshot
Device: Draeger Atlan A350 / A350 XL Anesthesia Workstations
Issue: Potential piston ventilator failure due to manufacturing defect
Original Correction: October 2024
Expansion: May 2026
FDA Classification: Class I
Potential Harm: Hypoxia, Bradycardia, cardiac arrest, death
Reported Injuries: 0
Reported Deaths: 0
Correction: Replacement of ventilator motor assembly
Interim Mitigation: Manual ventilation remains available if failure occurs
Intersurgical 22mm Smoothbore Breathing Tubes and Systems
FDA Issues Early Alert for Intersurgical Breathing Systems Over Potential Ventilation Failure. Manufacturing defect may cause breathing tube connectors to separate during use, potentially interrupting ventilation and exposing patients to serious injury or death.The...
FDA Early Alert: Teleflex/Arrow Guidewire
Affected guidewires and catheter products may release hydrophilic polymer particles into the bloodstream, potentially causing serious injury or death. No serious injuries or deaths have been reported.The U.S. Food and Drug Administration (FDA) has issued an Early...
FDA Investigates Cancer Risk with Zolgensma Gene Therapy
Postmarketing reports identify cases of tumor formation linked to gene therapy vector integration, prompting FDA to evaluate potential regulatory action.The U.S. Food and Drug Administration (FDA) is investigating a serious potential cancer risk associated with...
Eugia Vancomycin Recall: Glass Particle Contamination
FDA announces voluntary recall of a single lot of vancomycin hydrochloride for injection because of potentially dangerous particulate contamination.Eugia US LLC, formerly Auro Medics Pharma LLC, has initiated a voluntary nationwide recall of one lot of Vancomycin...
FDA Requires New GLP-1 Drug Warning for Vision Loss Risk
Agency cites potential increased risk of rare optic nerve condition following review of clinical trials and postmarket safety dataThe U.S. Food and Drug Administration (FDA) is requiring manufacturers of all glucagon-like peptide-1 receptor agonist (GLP-1 RA)...
Class 1 Recall for HemosIL AcuStar HIT Antibody Test
HemosIL AcuStar HIT-IgG(PF4-H). Source: fda.govPerformance problems could produce false-negative results, potentially delaying diagnosis of a dangerous reaction to heparin.The U.S. Food and Drug Administration (FDA) has identified a recall of certain lots of the...